Navigation Links
Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
Date:8/3/2011

WAYLAND, Mass., Aug. 3 , 2011) /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident. The contract totals $2.9 million over 2 years provided that key milestones are achieved. Should Avaxia's program meet its anticipated endpoints at the end of this contract, the company hopes to pursue future opportunities with BARDA.  

Dr. Barbara Fox, Avaxia's CEO, commented, "We are very pleased to receive this contract and are proud to be working on this program related to our country's national defense. With this funding, we will be advancing our oral antibody product through the key efficacy studies needed to support the product's use as a nuclear threat countermeasure. This contract will permit us to complete the pre-clinical pharmacology studies for this potential therapy. We look forward to working with BARDA to develop a novel drug that can effectively protect the gastrointestinal tract from radiation damage.

This award provides Avaxia with a new drug development program that is of significant benefit to the company.  Besides providing the company with additional scientific infrastructure, the research to be conducted on this therapeutic will contribute to and support our innovative technology platform and bolster work being done in the related field of inflammatory bowel disease.  Also, should the project meet its targets, the manufacturing and sales of a radiation mitigation drug will increase the commercial opportunities for the company."

About BARDA:  The Biomedical Advanced Research and Development Authority (BARDA), is part of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.  BARDA provides a comprehensive integrated portfolio approach to the advanced research and development, stockpile acquisition, innovation, and manufacturing infrastructure building of the necessary vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products for public health medical emergencies including chemical, biological, radiological, and nuclear threats, and pandemic influenza, and emerging infectious diseases. For additional information, visit www.hhs.gov/aspr.

About Avaxia Biologics, Inc.:  Avaxia Biologics (www.avaxiabiologics.com) is an early stage company developing oral antibody therapeutics that act locally within the gastrointestinal tract. The antibodies are designed to treat both diseases of the GI tract and metabolic diseases. Using its proprietary antibody platform, Avaxia is developing products for inflammatory bowel disease, oral mucositis, celiac disease, diabetes and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics, Inc. to Present Key Pre-Clinical Inflammatory Bowel Disease Remission Data at Biotech Showcase 2011
2. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Oral Antibody Therapeutic for Celiac Disease
3. Canada Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. China Orthopedic Devices Market Outlook to 2017 - Joint Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
5. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
6. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
7. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
8. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
9. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):